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ABSTRACT 
A modified biomaterial of periwinkle shell powder, MBPSP derivative of Tympanotonus fuscata shell was applied as a diluent in 
theophylline hydrate (TPH) and hydrochlorothiazide (HCTZ) tablets. A 100 g of the pulverized periwinkle shell was digested with 
166.0 ml of 2 M hydrochloric acid, filtered and neutralized with 5 M sodium hydroxide. Ortho-phosphoric acid was added drop wise 
until a thick, dehydrated mass was obtained. It was dried at 60 o C and milled to 250 μm size and designated as MBPSP. Using this, 
batches of granules containing TPH (100 mg) and HCTZ (50 mg) were produced by the wet granulation technique alongside lactose 
and dicalcium phosphate dihydrate (DCP). They were tableted at 7.55kN using a 10.50 mm diameter die and flat-faced punch on a 
hydraulic hand press. Tablet properties were evaluated. The weight variation for the TPH or HCTZ tablets produced from MBPSP, 
lactose or DCP were between 0.03- 0.32 %. The total drug content for the respective batches of tablets was within 85-118 % of the 
claimed label potency. Though the respective batches of tablets of TPH and HCTZ containing MBPSP, lactose or DCP maintained 
significantly high values of mechanical strength, the tablets of TPH and HCTZ prepared with DCP generally showed significantly 
higher values of mechanical strength than those of MBPSP and lactose. Dissolution profile showed that at 45.00 min, 73.13, 87.72 
and 87.45 % of TPH was released from the tablets containing lactose, MBPSP and DCP respectively while at 60.00 min, 64.58, 
57.84 and 66.00 % of HCTZ was dissolved from the tablets having lactose, MBPSP and DCP respectively. Though MBPSP 
compared significantly favourably with lactose and DCP in the various tablet parameters evaluated, the tablets of TPH or HCTZ 
comprising MBPSP displayed very significant shorter tablet disintegration time and also maintained a significantly greater 
mechanical strength in comparison to lactose and DCP. Therefore, MBPSP could be a very useful excipient in the formulation of 
TPH and HCTZ immediate-release tablets.  
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INTRODUCTION  
Tablets are compact dosage systems that comprise 
active pharmaceutical ingredient (API) and other inert 
substances described as excipients. It may or may not 
contain bulking agents. Tablets may be produced either 
by moulding or compression procedure. Tablets are 
widely used owing to their continuous advantages and 
appreciations by patients
1
. When a tablet is 
administered, it is anticipated to be moved to the spot 
where its active content will accomplish its therapeutic 
activities in its active form in the concentration that will 
be adequate and at the accurate rate to realize the 
therapeutic expectations. The tablet should be stable in 
its physical and chemical state in order to establish its 
potency, safety over its shelf life. The manufacture of a 
tablet is projected to be cost-effective and it should be 
appreciable for use by the patient
2
.  The composition of 
a tablet encompasses numerous ingredients besides the 
API. There are several sorts of excipients including the 
bulking agent, binder, lubricant, disintegrant, anti-
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adherent, a colouring agent, flavouring agent, etc
2
.  The 
utilization of excipients takes a vital position in the 
composition of tablets and other pharmaceutical dosage 
systems as they help in the production, safety, stability 
and therapeutic activity of any dosage form
3,4
. 
Excipients are also required in the formulation of a good 
tablet at the vital tablet press speed, assist in the flow, 
compressibility of powders as well as the capability of 
the tablet to be removed from the tablet press without 
crumbling.  Other use of the inert materials is that they 
aid in the mechanical strength, break-down, ecstasy, 
etc., and the overall functionality of the tablet
5
.  Tablets 
may be prepared by blending dry pulverized substances 
and compacting them into tablets in a method known as 
the direct compression (DC).    The powdered 
ingredients employed in the DC ought to remain mixed 
with other ingredients without segregation. In addition, 
such powder mixtures are anticipated to maintain 
effective flowability, compressibility and be removable 
from the tablet press without tablet defects. They are 
anticipated to possess enough mechanical strength and 
discharge the API in the expected time frame. 
Excipients that do not possess these qualities will be 
employed in tablet formulation by the wet granulation 
(WG) method. Excipients that are suitable for the WG 
method when blended will need to be kept stable 
without segregating by the use of an adhesive ingredient 
described as a binder or granulating agent. Some 
micronized ingredients require a degree of 
homogenizing before the addition of a granulating agent 
while some may not. However, wet massing attained by 
employing a binder may be likened to the manipulation 
of dough as in the manufacture of bread.  The 
subsequent wet mixture obtained is pushed through a 
suitable sieve size and dried at a regulated temperature. 
The dried form is rescreened over another lower 
aperture of sieves to yield granules.    
Tympanotonus fuscata var Radula (L) traditionally 
known as the periwinkle is protected with shell and fits 
in as a Mollusca, the major aquatic animal with 
exoskeleton defined as a shell. The blood of molluscs is 
rich in a liquid form of calcium which concentrates out 
and can crystallize as calcium carbonate. The layers of 
CaCO3 may integrate conchiolin which merges the 
CaCO3 crystals together. Large aggregates of shells 
might constitute sediment and become compacted into 
limestone 
6
. 
 In this work, the pulverized shell of Tympanotonus 
fuscata was modified and  employed as a bulking agent 
in the formulation of theophylline hydrate and 
hydrochlorothiazide tablets by the wet granulation 
method using lactose and dicalcium phosphate dihydrate 
(DCP) as standards. The processing and introductory 
assessment of the characteristics of the biomaterial of T. 
fuscata shell as pharmaceutical excipient has been 
documented 
6
. The physico-chemical characteristics of 
the modified biomaterial of Tympanotonus fuscata shell 
powder (MBPSP) considered as pharmaceutical 
excipient has also been acknowledged in the literature 
7
. 
Ugoeze and Udeala reported the application of a bio-ash 
derived from the periwinkle shell as a carbon dioxide 
(CO2) donor in the design of an effervescent low dose 
aspirin tablet 
8
. 
MATERIALS AND METHODS 
Materials 
The following were used as procured and includes: 
Lactose (Surechem, England), hydrochloric acid (HCl), 
sodium hydroxide (NaOH) (M&B, England), gelatin 
(Fisher, USA), lactose, dicalcium phosphate dihydrate 
(DCP) (Rousselot, Belgium), theophylline hydrate 
(TPH), corn starch, magnesium stearate, talc, ethanol 
(BDH, England) and hydrochlorothiazide (HCTZ) 
(donated by Juhel Nigeria Ltd).  
Methods 
Preparation of modified biomaterial of 
Tympanotonus fuscata shell powder  
The method reported by Ugoeze and Chukwu in the 
production of the modified biomaterial of 
Tympanotonus fuscata shell powder was adopted (7). A 
100 g quantity of the milled shell of Tympanotonus 
fuscata was digested with 166.0 ml of 2 M HCl and 
filtered. The clear acidic solution was neutralized with 5 
M NaOH to produce an abundant white precipitate 
which was washed severally. Ortho-phosphoric acid was 
added drop wise to the thick aqueous suspension of the 
precipitate until a thick, dehydrated mass was obtained. 
The mass was dried at 60 
o
 C in hot air oven (Uniscope, 
England). It was classified with a 250 μm stainless steel 
sieve (Retch, Germany) and stored in amber coloured 
powder container. This powder is referred to in this 
work as the modified biomaterial of periwinkle shell 
powder (MBPSP). 
Formulation of tablet 
Table 1: Formula for producing theophylline hydrate 
(TPH) tablets using MBPSP or lactose or DCP as 
diluents in wet granulation. Each tablet contains 100 mg 
of theophylline hydrate and weighs 300 mg.  
Ingredient Amount (% w/w) 
Theophylline hydrate (TPH) 33.33 
Gelatin 2.00 
Maize starch 10.00 
Magnesium stearate  0.50 
Talc 0.50 
Lactose or MBPSP or DCP 53.17 
Table 2: Formula for producing hydrochlorothiazide 
(HCTZ) tablets using MBPSP or lactose or DCP as 
diluents. Each tablet contains 50 mg of HCTZ and 
weighs 300 mg. 
Ingredient Amount (% w/w) 
Hydrochlorothiazide (HCTZ) 16.66 
Gelatin 2.00 
Corn starch 10.00 
Magnesium stearate 0.50 
Talc 0.50 
Lactose or MBPSP or DCP  69.84 
 
Granulation  
Granules containing TPH or HCTZ were produced by 
the method of wet granulation using the respective 
formulations shown in Tables 1 and 2. In each case, the 
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respective drugs were mixed with corn starch and the 
other diluents were added in bits and each time triturated 
to homogeneity. Gelatin dissolved in a little amount of 
hot water was added to the powder mix and triturated to 
yield a fairly wet mix which sprinkled with water in bits 
and kneaded. It was screened through sieve 10 (1.7 mm) 
and left in a hot air oven (Uniscope, England) at 60 
o 
C 
to dry to a constant weight.  The batches of the dried 
masses were rescreened with sieve 16 (1.00 mm) and 
the granules obtained were stored in airtight amber 
coloured glass containers.  
Compression of tablets 
The respective batches of granules prepared with TPH 
or HCTZ and containing MBPSP, lactose or DCP were 
lubricated with magnesium stearate and talc respectively 
and compressed for 30 s at a predetermined load of 7.35 
kN employing a 10.5 mm diameter die and flat-faced 
punches on a hydraulic hand press (Model C, Carver 
Laboratory Press, Menomonee Falls, WI. USA). All the 
compressed tablets were left for 24 h before they were 
analyzed to allow for possible recovery from stress. 
Evaluation of tablets  
Uniformity of tablet weight  
Twenty tablets were selected randomly from each batch 
of tablets of TPH or HCTZ prepared with either 
MBPSP, lactose or DCP were weighed one after the 
other on an electronic analytical balance (Mettler, 
Germany) 
9
.   
Uniformity of tablet thickness 
The thickness of the respective batches of tablets tested 
for uniformity of weight was measured with a 
micrometre screw gauge (VIS, Poland). 
Tablet hardness  
Ten tablets each from the batches of TPH or HCTZ 
prepared with either MBPSP, lactose of DCP were 
selected from each batch and their hardness (9) were 
evaluated using a digital hardness tester (DBK 
Instruments, England).  The mean hardness value was 
calculated. 
Tablet friability 
Ten tablets, each from TPH or HCTZ prepared either 
with MBPSP, lactose or DCP respectively were dusted 
and weighed. In turn, each was introduced in a tablet 
friabilator (Veego Tablet Friability Test Apparatus, 
India) set at 25 revolution per minute (rpm) for 4 min 
after which the tablets were respectively brought out, 
freed of dust and reweighed. Friability was calculated 
for the respective batches as per cent loss in weight of 
the entire tablets.  
Tablet disintegration time 
The disintegration time of six tablets from each batch 
containing TPH or HCTZ and containing either MBPSP, 
lactose or DCP was evaluated using disintegration 
apparatus (Veego Disintegration Apparatus, India). The 
instrument consists of a rigid basket-rack assembly 
holding six cylindrical glass tubes.  A 1L volume of 
0.1N HCl in a glass beaker was used as disintegrating 
medium, maintained at 37 ± 1
o
C. Disintegration was 
seen as complete when no residue of unbroken tablet 
remained on the screen of the test apparatus 
9
. 
Tablet total drug content 
Ten intact tablets of TPH or HCTZ prepared either with 
MBPSP, lactose or DCP were taken from each batch 
and crushed. The weight of powders equivalent to the 
mean weight of the respective batches was analyzed 
spectrophotometrically for its total drug content.   
Tablet tensile strength 
This was calculated from the equation:                
Dissolution rate test for tablets  
The dissolution rate for TPH or HCTZ tablets 
containing either MBPSP, lactose or DCP respectively 
were carried out using dissolution apparatus (Erweka 
DT 80, Germany) (apparatus 2, the paddle method and 
apparatus 1, the basket method, operated at the speed of 
50 and 100 revolutions per minute (rpm) for TPH and 
HCTZ tablets respectively each in 900 ml of 0.1 N HCl 
maintained at 37 ± 1
o 
C (9). For each procedure, a 5.0 ml 
of sample was withdrawn from the respective 
dissolution medium at time intervals between 5.0- 60.0 
min, replacing same with 5 ml of plain 0.1N HCl 
solution each time. The absorption of the samples was 
read in a Spectrophotometer 160-A (Japan) at the 
respective maximum wavelengths of 268 and 271 nm 
for TPH and HCTZ respectively.  
Statistical analysis 
All statistical analysis of data involving ANOVA was 
carried out using the IBM SPSS Statistics 20 software. 
RESULTS AND DISCUSSIONS 
Physical properties of tablets 
The characteristics of the TPH or HCTZ prepared with 
MBPSPS, lactose or DCP are shown in Tables 3 and 4 
respectively.  
Appearance of tablets 
The tablets of TPH and HCTZ produced with lactose, 
MBPSP or DCP were glossy without discolouration.  
Tablet weight uniformity and thickness 
The weight variation for the TPH or HCTZ tablets 
prepared with MBPSP, lactose or DCP were between 
0.03- 0.32 %. The British Pharmacopoeia 
9
 specified up 
to 7.5% for weight variation for tablets weighing 130-
324 mg. The low values of weight variation may be due 
to consistencies in the flow of granules at compression 
press. There were no significant differences in the 
weights of tablets in the respective batches of TPH and 
HCTZ between MBPSP and lactose (p>0.05), though, 
there was a slight difference in weight between MBPSP, 
lactose and DCP (p = 0.04). A similar observation was 
also recorded at the respective tablet thickness for TPH 
and HCTZ for all the diluents under study.
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Table 3: Properties of theophylline hydrate tablet prepared with MBPSP, lactose or DCP. 
Tablet parameter  MBPSP Lactose DCP 
Uniformity of weight (mg) 299.55±0.55 299.03±0.11 300.10±0.80 
Thickness (mm) 2.05±0.01 2.42±0.02 2.03.±0.01 
Drug Content (%) 90.10±0.01 89.72±0.04 96.76±0.05 
Disintegration time (min) 2.10 ± 0.10 4.13± 0.15 12.92±0.06 
Hardness (N) 143.39±0.37 100.43±0.08 215.00±0.02 
Friability (%) 0.60±0.02 0.51±0.02 0.90±0.02 
Tensile strength (mN/m
2
)  3349±0.61 2496.39±0.59 6389.39±0.56 
HFR
* 
217.57±0.11 193.36± 0.08 236.36±0.05 
*Hardness Friability Ratio. 
Table 4: Properties of hydrochlorothiazide tablets produced with MBPSP, lactose or DCP. 
Tablet parameter  MBPSP Lactose DCP 
Uniformity of weight (mg) 299.54±0.56 299.10±0.11 300.10±0.80 
Thickness (mm) 2.43±0.01 2.39±0.06 2.47±0.02 
Drug Content (%) 109.12±0.56 101.32±0.50 106.12±0.16 
Disintegration time (min) 1.99± 0.02 8.96± 0.05 10.95±0.08 
Hardness (N) 117.63±0.15 126.59±0.09 131.42±0.04 
Friability (%) 0.75± 0.02 0.52±0.02 0.43±0.03 
Tensile strength (mN/m
2
)  2914.49±0.09 3199.50±0.11 3213.61±0.11 
HFR
* 
158.52±0.04 235.30±0.03 320.79±0.09 
*Hardness Friability Ratio 
Total drug content 
Considering the total drug contents for TPH and HCTZ, 
statistical analysis showed significant differences in the 
total drug content across all the batches of TPH and 
HCTZ for MBPSP, lactose or DCP (p<0.05), but  no 
batch was below 85 % or above 115 % of the average 
content. The British Pharmacopoeia 
9
 specified that a 
product conforms to the test for total drug content if 
each individual content is in the range of 85 % and 115 
% of the average content.  
Tablet mechanical strength 
The force required to break the tablet is evaluated in 
kilogram or Newton. A tablet hardness of 4 kg (≈39 N) 
is generally measured to be the least for satisfactory 
tablets 
10
. Oral tablets normally have a hardness of 4 -10 
kg (≈39 – 98 N). Tablet hardness largely appreciates 
with regular storage of tablets and is influenced by the 
shape, chemical properties, binding agent and the 
compression pressure applied during compression 
11,12
.   
The friability test is closely correlated to tablet hardness 
and is designed to appraise the ability of the tablet to 
tolerate abrasion in packaging, handling and shipping. A 
friability of less than 1.00 % is considered good 
especially for tablets produced by wet granulation but 
tablets produced by direct compression can give 
friability higher than unity 
13
. 
Tensile strength is an added parameter employed to 
measure the mechanical properties of tablets. It is a 
measure of the bond strength of a tablet 
14
. 
The combination of the tablet hardness and friability, a 
term designated as the hardness-friability ratio (HFR) is 
another measure of mechanical strength of 
pharmaceutical tablets 
11, 12,15
. The hardness provides a 
measure of tablet strength while the friability is a 
measure of the tablet weakness. Studies have shown that 
the higher the HFR values, the stronger the tablet 
11,12
.   
However, the respective batches of tablets of TPH and 
HCTZ containing MBPSP, lactose or DCP maintained 
high values of mechanical strength with significant 
differences in the values of their tablet hardness, 
friability, tensile strength and hardness friability ratio 
(HFR) (p<0.05).  Tablets of TPH and HCTZ prepared 
with DCP generally showed higher values of mechanical 
strength than those of MBPSP and lactose. However, for 
the tablets of TPH, the order of mechanical strength was: 
DCP > MBPSP > lactose while in HCTZ, it was DCP > 
Lactose > MBPSP.  
Disintegration time 
For most uncoated tablets, the British Pharmacopoeia 
specifies that the tablets disintegrates in 15 min (even 
though it varies for some uncoated tablets) while for 
coated tablets, up to 2 hours may be required 
9, 16
. Thus, 
the tablet disintegration test is restricted to production 
control of lot to lot disparities in the respective products 
and is not a degree of bioavailability 
17
. Nevertheless, it 
is used to provide a simple and useful means for 
monitoring and controlling the quality of tablets. Ejiofor 
et al. 
18
 stated that disintegration time has a direct 
relationship to tablet hardness. 
Though the entire batches of TPH and HCTZ prepared 
with MBPSP, lactose or DCP disintegrated in less than 
15 min, there were significant differences across the 
respective batches of tablets of TPH and HCTZ prepared 
with MBPSP, lactose or DCP (p < 0.05), with the tablets 
prepared with MBPSP disintegrating within the shortest 
time frame for both TPH and HCTZ. The order of 
disintegration time was as follows: MBPSP < lactose < 
DCP for TPH and HCTZ respectively.  
 
Ugoeze et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(2):176-180           
ISSN: 2250-1177                                                                              [180]                                                                            CODEN (USA): JDDTAO 
Drug dissolution 
The dissolution profiles for TPH and HCTZ tablets are 
presented in Figures 1 and 2 respectively. The United 
States Pharmacopoeia (USP) 
19
 specified that not less 
than 80.00 % of the labelled amount of TPH should be 
dissolved in 45.00 min. For the tablet of HCTZ, the USP 
also specified that not less than 60.00 % of the labelled 
amount should be dissolved in 60.00 min. From the 
dissolution rate profile of TPH tablet, at 45.00 min, 
73.13, 87.72 and 87.45 % of TPH was released from the 
tablets prepared with lactose, MBPSP and DCP 
respectively (Figure 1) while for HCTZ tablets, at 60.00 
min, 64.58, 57.84 and 66.00 % of HCTZ was dissolved 
from the tablets prepared with lactose, MBPSP and DCP 
respectively (Figure 2). These results imply that the 
manufacture of TPH tablet using DCP and MBPSP as 
well as the preparation of HCTZ tablets using DCP and 
lactose complied with the USP requirements for drug 
release.   
CONCLUSION 
A new pharmaceutical excipient, MBPSP has been 
derived from the shell of the T. fuscata. It was applied as 
a diluent in the wet granulation method to produce TPH 
and HCTZ tablets in comparison with two commercial 
diluents, lactose and DCP. MBPSP compared very 
favourably with the commercial samples of lactose and 
DCP in the various tablet parameters used for 
evaluation. However, the tablets of TPH or HCTZ 
prepared with MBPSP displayed very significant shorter 
tablet disintegration time as well as maintaining a high 
value of mechanical strength. Therefore, the new 
excipient, MBPSP could be a very useful excipient in 
the formulation of TPH and HCTZ immediate-release 
tablets.  
 
Figure 1: Dissolution rate profile for theophylline hydrate 
tablet prepared with lactose, MBPSP or dicalcium 
phosphate dihydrate (DCP) in 0.1NHCl at 37±1
o 
C 
 
Figure 2: Dissolution profile for hydrochlorothiazide tablet 
prepared with lactose, MBPSP or dicalcium phosphate 
dihydrate in 0.1NHCL at 37±1
o 
C
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